Rotigotine transdermal patch for the treatment of Parkinson's Disease
Identifieur interne : 000F53 ( Main/Exploration ); précédent : 000F52; suivant : 000F54Rotigotine transdermal patch for the treatment of Parkinson's Disease
Auteurs : Santiago Perez-Lloret [France, Argentine] ; Maria Veronica Rey [France] ; Pietro Lucca Ratti [France] ; Olivier Rascol [France]Source :
- Fundamental & clinical pharmacology [ 0767-3981 ] ; 2013.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe restless legs syndrome (RLS). FDA originally granted a marketing authorization for early PD, which was later suspended, and is now studying the authorization for RLS. The aim of this review is to review the pharmacokinetics, pharmacodynamics as well as the clinical efficacy and tolerability of the rotigotine transdermal patch in PD. Source material was identified using a PubMed search for the term 'rotigotine' and PD. Articles published up to January 2011 or abstract submitted to most relevant international neurology congresses were reviewed. The rotigotine transdermal patch is efficacious for the treatment of PD. Tolerability profile appears to be well within the range of that observed with other non-ergot dopamine agonists in PD. Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on the possibility that continuous dopamine stimulation by means of the transdermal patch has any influence on levodopa-related motor complications.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000133
- to stream PascalFrancis, to step Curation: 001157
- to stream PascalFrancis, to step Checkpoint: 000083
- to stream Main, to step Merge: 000F81
- to stream Main, to step Curation: 000F53
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rotigotine transdermal patch for the treatment of Parkinson's Disease</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research</s1><s2>Buenos Aires</s2><s3>ARG</s3><sZ>1 aut.</sZ></inist:fA14><country>Argentine</country><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Veronica Rey, Maria" sort="Veronica Rey, Maria" uniqKey="Veronica Rey M" first="Maria" last="Veronica Rey">Maria Veronica Rey</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ratti, Pietro Lucca" sort="Ratti, Pietro Lucca" uniqKey="Ratti P" first="Pietro Lucca" last="Ratti">Pietro Lucca Ratti</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0074112</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0074112 INIST</idno><idno type="RBID">Pascal:13-0074112</idno><idno type="wicri:Area/PascalFrancis/Corpus">000133</idno><idno type="wicri:Area/PascalFrancis/Curation">001157</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000083</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000083</idno><idno type="wicri:doubleKey">0767-3981:2013:Perez Lloret S:rotigotine:transdermal:patch</idno><idno type="wicri:Area/Main/Merge">000F81</idno><idno type="wicri:Area/Main/Curation">000F53</idno><idno type="wicri:Area/Main/Exploration">000F53</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rotigotine transdermal patch for the treatment of Parkinson's Disease</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research</s1><s2>Buenos Aires</s2><s3>ARG</s3><sZ>1 aut.</sZ></inist:fA14><country>Argentine</country><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Veronica Rey, Maria" sort="Veronica Rey, Maria" uniqKey="Veronica Rey M" first="Maria" last="Veronica Rey">Maria Veronica Rey</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ratti, Pietro Lucca" sort="Ratti, Pietro Lucca" uniqKey="Ratti P" first="Pietro Lucca" last="Ratti">Pietro Lucca Ratti</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1><s2>31059, TOULOUSE</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Fundamental & clinical pharmacology</title><title level="j" type="abbreviated">Fundam. clin. pharmacol.</title><idno type="ISSN">0767-3981</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Fundamental & clinical pharmacology</title><title level="j" type="abbreviated">Fundam. clin. pharmacol.</title><idno type="ISSN">0767-3981</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term><term>Dopamine agonist</term><term>Parkinson disease</term><term>Patch</term><term>Percutaneous route</term><term>Restless legs syndrome</term><term>Rotigotine</term><term>Safety</term><term>Toxicity</term><term>Transdermal system</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Rotigotine</term><term>Voie percutanée</term><term>Système transdermique</term><term>Patch</term><term>Traitement</term><term>Maladie de Parkinson</term><term>Stimulant dopaminergique</term><term>Efficacité traitement</term><term>Syndrome des jambes sans repos</term><term>Toxicité</term><term>Sécurité</term><term>Antiparkinsonien</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe restless legs syndrome (RLS). FDA originally granted a marketing authorization for early PD, which was later suspended, and is now studying the authorization for RLS. The aim of this review is to review the pharmacokinetics, pharmacodynamics as well as the clinical efficacy and tolerability of the rotigotine transdermal patch in PD. Source material was identified using a PubMed search for the term 'rotigotine' and PD. Articles published up to January 2011 or abstract submitted to most relevant international neurology congresses were reviewed. The rotigotine transdermal patch is efficacious for the treatment of PD. Tolerability profile appears to be well within the range of that observed with other non-ergot dopamine agonists in PD. Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on the possibility that continuous dopamine stimulation by means of the transdermal patch has any influence on levodopa-related motor complications.</div></front></TEI><affiliations><list><country><li>Argentine</li><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></region><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Ratti, Pietro Lucca" sort="Ratti, Pietro Lucca" uniqKey="Ratti P" first="Pietro Lucca" last="Ratti">Pietro Lucca Ratti</name><name sortKey="Ratti, Pietro Lucca" sort="Ratti, Pietro Lucca" uniqKey="Ratti P" first="Pietro Lucca" last="Ratti">Pietro Lucca Ratti</name><name sortKey="Veronica Rey, Maria" sort="Veronica Rey, Maria" uniqKey="Veronica Rey M" first="Maria" last="Veronica Rey">Maria Veronica Rey</name><name sortKey="Veronica Rey, Maria" sort="Veronica Rey, Maria" uniqKey="Veronica Rey M" first="Maria" last="Veronica Rey">Maria Veronica Rey</name></country><country name="Argentine"><noRegion><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:13-0074112
|texte= Rotigotine transdermal patch for the treatment of Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.29. |  |